H.C. Wainwright reaffirmed its buy rating on BioStem Technologies (NASDAQ: BSEM) on Monday, maintaining a 12-month price target of $7.00 per share.
The reiteration follows the company’s Q2 2026 financial results, which showed revenue of $7.9 million, a 29% sequential increase from $6.1 million in Q1. The hospital channel contributed $6.7 million, or roughly 85% of total revenue, marking the first sequential growth since CMS reimbursement adjustments took effect in January 2026. The physician office channel accounted for the remaining revenue.
BioStem reported a net loss of $0.52 per diluted share, underperforming analyst expectations of an $0.08 loss per share on $11 million in revenue. Despite the miss, the company raised its full-year sales guidance, citing expected growth in the hospital sector.
The analyst firm’s price target implies a potential 98% upside from BioStem’s closing price of $3.54 on August 22. H.C. Wainwright’s valuation remains above InvestingPro’s fair value estimate of $4.07 per share.
BioStem’s Q2 results reflect the integration of surgical and wound care assets acquired from BioTissue in January 2026, a strategic shift toward a hospital-focused commercial model. The company’s transition has driven sequential revenue growth for the first time since CMS adjustments were implemented earlier this year.
